Q2 FY2026 · ended Jun 30, 2026 · Revenue $388.18M, +2.7% YoY · Filed Aug 6, 2026
Lantheus Holdings, Inc. (LNTH) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $388.2 million and net income of $75.0 million. As of Jun 30, 2026 it held $593.3 million in cash and investments and $55.7 million in total debt.
Revenue
$388.18M
+2.7% vs year-ago quarter
Net income
$75.03M
-4.7% vs year-ago quarter
Operating cash flow
$92.20M
+5.9% vs year-ago quarter
Free cash flow
—
EPS
$1.11
-0.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
65.27M
-4.0% vs year-ago quarter
Net cash
$537.59M
Q2 FY2026
Operating margin
19.4%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- LNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1521036
- Former names
- Lantheus MI Holdings, Inc. (until May 23, 2014)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $388.2M | $377.3M | $406.8M | $384.0M | $378.0M |
| Operating income | $100.2M | $81.3M | $77.2M | $43.6M | $88.0M |
| Net income | $75.0M | $118.4M | $54.1M | $27.8M | $78.8M |
| Diluted EPS | $1.11 | $1.80 | $0.81 | $0.41 | $1.12 |
| Operating cash flow | $92.2M | $125.1M | $90.2M | $105.3M | $87.1M |
| Total assets | $2.4B | $2.3B | $2.2B | $2.3B | $2.1B |
| Total liabilities | $1.1B | $1.1B | $1.1B | $1.2B | $949.3M |
| Stockholders' equity | $1.3B | $1.2B | $1.1B | $1.1B | $1.2B |
| Cash and investments | $593.3M | $498.6M | $359.1M | $382.0M | $695.6M |
| Total debt | $55.7M | $57.5M | $55.8M | $53.0M | $49.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 17, 2026 |
All 1003 Lantheus Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.